Asumlea
First Denosumab biosimilar in Argentina for the treatment of osteoporosis. Potent, versatile agent to prevent osteoporotic fractures in the short and long term.
Therapeutic Area
Drug product to treat bone diseases; other agents modifying both bone structure and mineralization.
Active Ingredient
Denosumab
Line
Osteoarticular
Dosage forms
60 mg/ml pre-filled syringe x 1
